Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome

American Journal of Cardiology

Volumn 91, Issue 8, 2003, Pages 956-960

  Vega, Gloria Lena ^a   Ma, Patrick T S ^b   Cater, Nilo B ^b   Filipchuk, Neil ^b   Meguro, Shinichi ^b   Garcia Garcia, Ana Barbara ^b   Grundy, Scott M ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; FENOFIBRATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERLIPIDEMIA; LOW DRUG DOSE; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0037446467     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00111-5     Document Type: Article

References (30)

1. East C., Bilheimer D.W., Grundy S.M. Combination drug therapy for familial combined hyperlipidemia. Ann Intern Med. 109:1988;25-32.
2. Vega G.L., Grundy S.M. Influence of lovastatin therapy on metabolism of low density lipoproteins in mixed hyperlipidaemia. J Intern Med. 230:1991;341-350.
3. Shek A., Ferrill M.J. Statin-fibrate combination therapy. Ann Pharmacother. 35:2001;908-917.
4. Mantel-Teeuwisse A.K., Klungel O.H., Herings R.M., van Puijenbroek E.P., Porsius A.J., de Boer A. Myopathy due to statin/fibrate use in The Netherlands. Ann Pharmacother. 36:2002;1957-1960.
5. Staffa J.A., Chang J., Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med. 346:2002;539-540.
6. Kyrklund C., Backman J.T., Kivisto K.T., Neuvonen M., Laitila J., Neuvonen P.J. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther. 69:2001;340-345.
7. Prueksaritanont T., Zhao J.J., Ma B., Roadcap B.A., Tang C., Qiu Y., Liu L., Lin J.H., Pearson P.g, Baillie T.A. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther. 301:2002;1042-1051.
8. Pan W.J., Gustavson L.E., Achari R., Rieser M.J., Ye X., Gutterman C., Wallin B.A. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol. 40:2000;316-323.
9. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497.
10. Krauss R.M., Burke D.J. Identification of multiple subclasses of plasma low-density lipoproteins in normal humans. J Lipid Res. 23:1982;97-104.
11. Kazumi T., Kawaguchi A., Hozumi T., Nagao M., Iwahashi M., Hayakawa M., Ishihara K., Yoshino G. Low density lipoprotein particle diameter in young, nonobese, normolipidemic Japanese men. Atherosclerosis. 142:1999;113-119.
12. Kuller L., Arnold A., Tracy R., Otvos J., Burke G., Psaty B., Siscovick D., Freedman D.S., Kronmal R. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol. 2:2002;1175-1180.
13. Kulkarni K.R., Garber D.W., Jones M.K., Segrest J.P. Identification and cholesterol quantification of low density lipoprotein classes in young adults by VAP-II methodology. J Lipid Res. 36:1995;2291-2302.
14. National Cholesterol Education Program second report of the Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol (Adult Treatment Panel II) . Circulation. 89:1994;1333-1445.
15. Bachorik P.S., Lovejoy K.L., Carroll M.D., Johnson C.L. Apolipoprotein B and AI distributions in the United States, 1988-1991 results of the National Health and Nutrition Examination Survey III(NHANES III) . Clin Chem. 43:1997;2364-2378.
16. Goldstein J.L., Hazzard W.R., Schrott H.G., Bierman E.L., Motulsky A.G. Hyperlipidemia in coronary heart disease. I. Lipid levels in 500 survivors of myocardial infarction. J Clin Invest. 52:1973;1533-1543.
17. Austin M.A., McKnight B., Edwards K.L. Cardiovascular disease mortality in familial forms of hypertriglyceridemia a 20-year prospective study . Circulation. 101:2000;2777-2782.
18. Assmann G., Schulte H., von Eckardstein A., Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 124:(suppl):S11-S20):1996.
19. Hokanson J.E., Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level a meta-analysis of population-based prospective studies . J Cardiovasc Risk. 3:1996;213-219.
20. Austin M.A., Breslow J.L., Hennekens C.H., Buring J.E., Willett W.C., Krauss R.M. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 260:1988;1917-1921.
21. McKenney J.M., McCormick L.S., Schaefer E.J., Black D.M., Watkins M.L. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol. 88:2001;270-274.
22. Miller M., Dolinar C., Cromwell W., Otvos J.D. Effectiveness of high doses of simvastatin as monotherapy in mixed hyperlipidemia. Am J Cardiol. 87:2001;232-234.
23. Otvos J.D., Shalaurova I., Freedman D.S., Rosenson R.S. Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. Atherosclerosis. 160:2002;41-48.
24. Frick M.H., Elo O., Haapa K., Heinonen O.P., Heinsalmi P., Helo P., Huttunen J.K., Kaitaniemi P., Koskinen P., Manninen V., et al. Helsinki Heart Study primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease . N Engl J Med. 317:1987;1237-1245.
25. Rubins HB, Robins SJ, Collins. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999;341:410-418.
26. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study: a randomised study. Lancet 2001;357:905-910.
27. Ericsson C.G., Hamsten A., Nilsson J., Grip L., Svane B., de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 347:1996;849-853.
28. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation2000;102:21-27.
29. Canner P.L., Berge K.G., Wenger N.K., Stamler J., Friedman L., Prineas R.J., Friedewald W. Fifteen year mortality in Coronary Drug Project patients long-term benefit with niacin . J Am Coll Cardiol. 8:1986;1245-1255.
30. Carlson L.A., Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 223:1988;405-418.